In a completed investigator-sponsored Phase 1/2 clinical trial in 83 patients with advanced hematologic cancers, a single cycle of SL-401 alone demonstrated anti-tumor activity,
While we believe these industry publications and third party research, surveys and studies are reliable, we have not independently verified such data.8Table of ContentsThe offeringCommon stock offered by usshares of our common stockCommon stock to be outstanding after this offeringsharesOption to purchase additional sharesThe underwriters have an option for a period of 30 days to purchase up to additional shares of our common stock.Use of proceedsWe intend to use the net proceeds from this offering for clinical development of SL-401 in multiple hematologic cancer indications, including planned pivotal programs in BPDCN and third-line AML;
"Incorporation of Documents by Reference."10Table of ContentsPeriod fromAugust 8,2003(inception) toJune 30,2013Year ended December 31,Six months ended June 30,20102011201220122013(unaudited)(unaudited)(unaudited)Statement of operations data:Operating expenses:Research and development$1,329,509$1,629,026$3,376,962$1,613,340$7,246,247$18,691,915General and administrative930,3311,088,0283,090,6111,372,1523,238,89312,723,689Total operating expenses2,259,8402,717,0546,467,5732,985,49210,485,14031,415,604Loss from operations(2,259,840)(2,717,054)(6,467,573)(2,985,492)(10,485,140)(31,415,604)Other income:484,90546,673301,68412,46030,649966,167Other expense—(9,670)(35)(35)—(9,705)Interest expense(69,493)(98,643)(118,765)(50,038)(505,037)(801,987)Interest income43,04524,0689,9077,8823,244963,827Net loss$(1,801,383)$(2,754,626)$(6,274,782)$(3,015,223)$(10,956,284)$(30,297,302)Less: accretion of preferred stock dividends(239,720)————(2,591,165)Add: discount on redemption of preferred stock12,171,765————12,171,765Net (loss) / income attributable to common stockholders$10,130,662$(2,754,626)(6,274,782)$(3,015,223)$(10,956,284)$(20,716,702)Net (loss) / income attributable to common stockholders per common share:Basic$3.07$(0.80)$(1.82)$(0.88)$(1.37)Diluted$2.81$(0.80)$(1.82)$(0.88)$(1.37)Weighted average number of common shares:Basic3,298,7933,441,9953,441,9953,441,9958,014,529Diluted3,607,0303,441,9953,441,9953,441,9958,014,529The following summary unaudited balance sheet data as of June 30, 2013 is presented:•on an actual basis; and•on an as adjusted basis to give effect to our sale of shares of common stock in this offering at the assumed offering
condition could suffer materially, the trading price of our common stock could decline and you could lose all or part of your investment.Risks related to development, clinical testing and regulatory approval of our product candidatesWe are heavily dependent on the success of our two lead product candidates, SL-401 and SL-701, and we cannot provide any assurance that any of our product candidates will be
and efficacy, clinical trials and commercial sales, pricing and distribution of our product candidates, and we cannot predict success in these jurisdictions.Clinical drug development involves a lengthy and expensive process with an uncertain outcome.Clinical testing is expensive and, depending on the stage of development, can take a substantial amount of time to complete.
unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable and depends upon numerous factors, including the
any commercially viable drugs to treat human patients with cancer.If we are not successful in discovering, developing and commercializing additional product candidates, our ability to expand our business and achieve our strategic
market price of our common stock also could cause you to lose all or a part of your investment.We will require additional financing to achieve our goals, and a failure to obtain this capital when needed could force us to delay, limit, reduce or terminate our product
and clinical trials;•the ability of our product candidates to progress through clinical development successfully;•the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates;•the cost of commercialization activities if any of our product candidates are approved for sale, including marketing,
litigation costs and the outcome of such litigation;•the timing, receipt and amount of sales of, or royalties on, our future products, if any;•our need and ability to hire additional management and scientific and medical personnel;•the effect of competing technological and market developments; and•our need to implement additional internal systems and infrastructure, including financial and reporting systems.Additional
strategic partners;•gain market acceptance for our products;•develop and maintain any strategic relationships we elect to enter into;•satisfy our obligations under our in-license agreements; and•manage our spending as costs and expenses increase due to drug discovery, preclinical development, clinical trials,
we are unsuccessful in accomplishing these objectives, we may not be able to develop product candidates, raise capital, expand our business or continue our operations.We face substantial competition, which may result in others discovering, developing or commercializing products before, or more successfully, than we do.Our future success depends on our ability to demonstrate and maintain a competitive advantage with respect to the design, development and
effectively against our current and future competitors, our business will not grow and our financial condition and operations will suffer.If we fail to attract and keep senior management and key scientific personnel, we may be unable to successfully develop our product candidates, conduct our clinical trials
successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.We may encounter difficulties in managing our growth and expanding our operations successfully.As we seek to advance our product candidates through clinical trials, we will need to expand our development, regulatory, manufacturing, marketing
Regardless of the merits or eventual outcome, liability claims may result in:•decreased demand for our product candidates or products that we may develop;•injury to our reputation;•withdrawal of clinical trial participants;•costs to defend the related litigation;•a diversion of management's time and our resources;•substantial monetary awards to trial participants or patients;•product recalls, withdrawals or labeling, marketing or promotional restrictions;•loss of revenue;•the inability to commercialize our product candidates; and•a decline in our stock price.Our
Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.Risks related to commercialization of our product candidatesIf, in the future, we are unable to establish our own sales, marketing and distribution capabilities or enter into licensing or collaboration agreements for these purposes,
healthcare providers, patients, third-party payors and, in the cancer market, acceptance by the major operators of cancer clinics.Even if SL-401, SL-701 or any other product candidate that we may develop or acquire in the future obtains regulatory approval, the product may not
that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.30Table of ContentsHealthcare policy changes may have a material adverse effect on us.Our business may be affected by the efforts of government and third-party payors to contain or reduce the cost of healthcare through various means.
products for sale in our major commercial markets.•We may not develop additional proprietary technologies that are patentable.•The patents of others may have an adverse effect on our business.Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents.
of the factors that we believe could cause actual results to differ from those anticipated or predicted include:•the success and timing of our preclinical studies and clinical trials;•our ability to obtain and maintain regulatory approval of our product candidates, and the labeling under any approval we